The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas
Authors:
- 1 February 2015
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 402, 64-71
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (30971005)
- Beijing Natural Science Foundation (7144198)
- Research Special Fund for Public Welfare Industry of Health (201402008)
This publication has 27 references indexed in Scilit:
- TGFβ signalling in contextNature Reviews Molecular Cell Biology, 2012
- A Local Paracrine and Endocrine Network Involving TGFβ, Cox-2, ROS, and Estrogen Receptor β Influences Reactive Stromal Cell Regulation of Prostate Cancer Cell MotilityMolecular Endocrinology, 2012
- A Cell-Based High-Content Screening Assay Reveals Activators and Inhibitors of Cancer Cell InvasionScience Signaling, 2011
- Dopamine agonist–resistant prolactinomasJournal of Neurosurgery, 2011
- Active and Total Transforming Growth Factor-β1 Are Differentially Regulated by Dopamine and Estradiol in the PituitaryEndocrinology, 2011
- Medical treatment of prolactinomasNature Reviews Endocrinology, 2011
- TGFβ in CancerCell, 2008
- Ethanol Alters Production and Secretion of Estrogen‐Regulated Growth Factors That Control Prolactin‐Secreting Tumors in the PituitaryAlcohol, Clinical and Experimental Research, 2007
- Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasisCytokine & Growth Factor Reviews, 2006
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002